Thank you so much for the presentation! I have one question; as far as i know, pre-clinical studies test the vaccine on mice, and younger ones make stronger primary responses than those of the older ones. but in clinical studies, these vaccines are mainly tested on older people, when thymus has already stopped producing naive t-cells for many years. wouldn't this lead to a discrepancy between pre-clinical and clinical studies? how do you make sure to get accurate responses to the vaccine when the test pool is not diversified?
0000000
Giriş yapmamıs kullanıcılar 'Yorum Gönderisi' eylemini kullanamazlar.
M
Thank you so much for the presentation! I have one question; as far as i know, pre-clinical studies test the vaccine on mice, and younger ones make stronger primary responses than those of the older ones. but in clinical studies, these vaccines are mainly tested on older people, when thymus has already stopped producing naive t-cells for many years. wouldn't this lead to a discrepancy between pre-clinical and clinical studies? how do you make sure to get accurate responses to the vaccine when the test pool is not diversified?